Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis

References

• Dobruch J, Oszczudłowski M. Bladder cancer: current challenges and future directions. Medicina. 2021;57(8):749. doi:10.3390/medicina57080749
   PubMedGoogle Scholar
• Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci. 2020;8(1):15. doi:10.3390/medsci8010015
   Google Scholar
• Babjuk M, Burger M, Compérat E, et al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Eur Assoc Urol. 2021;71:447–461. doi:10.1016/j.eururo.2016.05.041
   Google Scholar
• Goutas D, Tzortzis A, Gakiopoulou H, Vlachodimitropoulos D, Giannopoulou I, Lazaris AC. Contemporary molecular classification of urinary bladder cancer. Vivo. 2021;35(1):75–80. doi:10.21873/invivo.12234
   PubMed Web of Science ®Google Scholar
• Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–795. doi:10.1016/j.eururo.2018.09.001
   PubMed Web of Science ®Google Scholar
• Todenhöfer T, Maas M, Ketz M, et al. Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB. World J Urol. 2021;39(8):2953–2960. doi:10.1007/s00345-020-03587-0
   PubMed Web of Science ®Google Scholar
• NCI. Cancer of the urinary bladder - Cancer stat facts (1/24/2022); 2020.
   Google Scholar
• Teoh JY-C, Huang J, Ko WY-K, et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol. 2020;78(6):893–906. doi:10.1016/j.eururo.2020.09.006
   PubMed Web of Science ®Google Scholar
• Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2017;119(3):371–380. doi:10.1111/bju.13760
   PubMed Web of Science ®Google Scholar
• Siddiqui MR, Grant C, Sanford T, Agarwal PK. Current clinical trials in non–muscle invasive bladder cancer. Urol Oncol. 2017;35(8):516–527. doi:10.1016/j.urolonc.2017.06.043
   PubMed Web of Science ®Google Scholar
• S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. AWMF-Registernummer: 032/038OL; Langversion 2.0; 2020. Available from: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Blasenkarzinom/Version_2.0/LL_Harnblasenkarzinom_Langversion_2.0.pdf. Accessed March 21, 2023.
   Google Scholar
• National Comprehensive Cancer Network. Available from: https://www.nccn.org/. Accessed November 26, 2020.
   Google Scholar
• Packiam VT, Johnson SC, Steinberg GD. Non-muscle-invasive bladder cancer: intravesical treatments beyond Bacille Calmette-Guérin. Cancer. 2017;123(3):390–400. doi:10.1002/cncr.30392
   PubMed Web of Science ®Google Scholar
• Packiam VT, Richards J, Schmautz M, Heidenreich A, Boorjian SA. The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer. Curr Opin Urol. 2021;31(3):178–187. doi:10.1097/mou.0000000000000863
   PubMed Web of Science ®Google Scholar
• Evers J, Grotenhuis AJ, Aben KKH, Kiemeney L, Vrieling A, Amankwah EK. No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression. PLoS One. 2020;15(3):e0229384. doi:10.1371/journal.pone.0229384
   PubMed Web of Science ®Google Scholar
• Williams SB, Howard LE, Foster ML, et al. Estimated Costs and long-term outcomes of patients with high-risk non–muscle-invasive bladder cancer treated with bacillus Calmette-Guérin in the veterans affairs health system. JAMA Network Open. 2021;4(3):e213800. doi:10.1001/jamanetworkopen.2021.3800
   PubMed Web of Science ®Google Scholar
• Bree KK, Shan Y, Hensley PJ, et al. Management, surveillance patterns, and costs associated with low-grade papillary stage ta non-muscle-invasive bladder cancer among older adults, 2004–2013. JAMA Netw Open. 2022;5(3):e223050. doi:10.1001/jamanetworkopen.2022.3050
   PubMed Web of Science ®Google Scholar
• Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the European Union. Eur Urol. 2016;69(3):438–447. doi:10.1016/j.eururo.2015.10.024
   PubMed Web of Science ®Google Scholar
• Lee LJ, Kwon CS, Forsythe A, Mamolo CM, Masters ET, Jacobs IA. Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews. Clinicoecon Outcomes Res. 2020;12:693–709. doi:10.2147/ceor.s274951
   PubMed Web of Science ®Google Scholar
• Witjes JA, Palou J, Soloway M, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int. 2013;112(6):742–750. doi:10.1111/bju.12012
   PubMed Web of Science ®Google Scholar
• Smith EJ, Maclennan S, Bjartell A, et al. Ensuring consistent European-wide urological care by the use of evidence-based clinical practice guidelines: can we do better. Biomed Hub. 2017;2(Suppl. 1):1–7. doi:10.1159/000479725
   Google Scholar
• The national association of statutory health insurance funds. Available from: https://www.gkv-spitzenverband.de/english/about_us/about_us.jsp. Accessed January 20, 2022.
   Google Scholar
• Ferlay JEM, Lam F, Colombet M, et al. Global cancer observatory: cancer today; 2020. Available from: https://gco.iarc.fr/today. Accessed April 22, 2022.
   Google Scholar
• Contieri R, Lughezzani G, Buffi NM, et al. Could we safely avoid a second resection in selected patients with T1 non-muscle-invasive bladder cancer? Preliminary results of cost-effectiveness study from humanitas new indications for ReTUR (HuNIRe) multicenter prospective trial. Front Oncol. 2022;12:879399. doi:10.3389/fonc.2022.879399
   PubMed Web of Science ®Google Scholar
• Mossanen M, Wang Y, Szymaniak J, et al. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol. 2019;37(10):2059–2065. doi:10.1007/s00345-018-2550-x
   PubMed Web of Science ®Google Scholar
• Yang M, Georgieva MV, Bocharova I, et al. The impact of progression on healthcare resource utilization and costs among patients with high-grade non-muscle invasive bladder cancer after bacillus Calmette-Guérin therapy: a retrospective SEER-medicare analysis. Adv Ther. 2021;38(3):1584–1600. doi:10.1007/s12325-020-01616-3
   PubMed Web of Science ®Google Scholar
• Jung A, Nielsen ME, Crandell JL, et al. Health-related quality of life among non-muscle-invasive bladder cancer survivors: a population-based study. BJU Int. 2020;125(1):38–48. doi:10.1111/bju.14888
   PubMed Web of Science ®Google Scholar
• Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, end points, and clinical trial designs for non–muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol. 2016;34(16):1935–1944. doi:10.1200/jco.2015.64.4070
   PubMed Web of Science ®Google Scholar
• Lee CT, Barocas D, Globe DR, et al. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. J Urol. 2012;188(6):2114–2119. doi:10.1016/j.juro.2012.08.005
   PubMed Web of Science ®Google Scholar
• Broughton EI, Chun DS, Gooden KM, Mycock KL, Rajkovic I, Taylor-Stokes G. Treatment and disease management patterns for bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia. Curr Urol. 2021. doi:10.1097/cu9.0000000000000072
   Google Scholar
• Narayan VM, Dinney CPN. Intravesical Gene Therapy. Urol Clin North Am. 2020;47(1):93–101. doi:10.1016/j.ucl.2019.09.011
   PubMed Web of Science ®Google Scholar
• Joshi M, Atlas SJ, Beinfeld M, et al. Cost-effectiveness of nadofaragene firadenovec and pembrolizumab in bacillus Calmette-Guerin immunotherapy unresponsive non-muscle invasive bladder cancer. Value Health. 2022. doi:10.1016/j.jval.2022.12.005
   PubMedGoogle Scholar